Brian Desmond, MD
Ophthalmology · Bend, ORNPI 1356329809
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Rxsight Inc at 54.3% of the total. 2025 is the largest year on record at $6,696, more than ten times the $69 reported in 2019. Among ophthalmology clinicians in OR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 90 payments — averaging $107.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$5K
- Carl Zeiss Meditec USA, Inc.$3K
- Alcon$799
- Johnson & Johnson Surgical Vision, Inc.$335
- Glaukos Corporation$239
- AbbVie$187
- plus $358 from 11 others
What the payments were for
- Consulting fees$4,62348%
- Travel & lodging$2,11622%
- Food & beverage$2,94430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 18 | $5,258 |
| Carl Zeiss Meditec USA, Inc. | 14 | $2,507 |
| Alcon | 20 | $799 |
| Johnson & Johnson Surgical Vision, Inc. | 10 | $335 |
| Glaukos Corporation | 4 | $239 |
| AbbVie(2 entities) | 8 | $187 |
| Sun Pharmaceutical Industries Inc. | 3 | $59 |
| Bausch & Lomb Americas Inc. | 3 | $57 |
| Sight Sciences, Inc. | 1 | $56 |
| Aerie Pharmaceuticals, Inc. | 2 | $44 |
| Dompe US, Inc. | 1 | $25 |
| Thea Pharma Inc. | 1 | $23 |
| Shire North American Group Inc | 1 | $23 |
| Astellas Pharma US Inc | 1 | $22 |
| Oyster Point Pharma, Inc. | 1 | $18 |
| Tarsus Pharmaceuticals, Inc. | 1 | $16 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT CONTACT LENS$4,846
- RXSIGHT INJECTOR CARTRIDGE$4,846
- RXSIGHT INJECTOR HANDPIECE$4,846
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$4,846
- LIGHT ADJUSTABLE LENS (LAL)$4,732
- ARTEVO 800$673
- Clareon$245
- CIRRUS HD-OCT$209
- IOLMaster 700$209
- VisuMax$209
- QUATERA 700$209
- ARGOS$183
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$114
How this compares
$9,683 in reported general payments places this provider in the 90th percentile of 248 ophthalmology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 39 | $14,143 |
| LumiganBimatoprost | 17 | $11,307 |
| Brimonidine Tartrate | 186 | $9,158 |
| Latanoprost | 576 | $8,731 |
| Prednisolone Acetate | 134 | $5,406 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 281 | $4,798 |
| Timolol Maleate | 138 | $3,801 |
| TafluprostTafluprost/Pf | 15 | $3,400 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 15 | $3,012 |
| Travoprost | 15 | $2,372 |
| Difluprednate | 18 | $1,605 |
| Bimatoprost | 11 | $1,427 |
| Ketorolac Tromethamine | 53 | $1,084 |
| Dorzolamide Hcl | 46 | $816 |
| Pilocarpine Hcl | 13 | $678 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aerie Pharmaceuticals, Inc.Rhopressa | $44 | $14,14339 claims |
| AbbVieLumigan | $187 | $11,30717 claims |
| AlconSimbrinza | $799 | $3,01215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 248 ophthalmology providers in Oregon.
Other ophthalmology in Bend
- Kurt AndreasonBend$13K
- Thomas FitzsimmonsBend$4K
- Patricia BuehlerBend$3K
- Meryl SundyBend$3K
- David HuangCorvallis$67K
- Mark PennesiPortland$56K
- Rene ChoiPortland$21K
- Balamurali AmbatiEugene$19K
- Richard HoffmanEugene$17K
- Bart AdamsPendleton$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.